caspofungin + clindamycin

Caspofungin + clindamycin is a combination therapy used primarily as a salvage or alternative treatment for Pneumocystis jirovecii pneumonia (PCP), especially in patients who are intolerant of or have failed standard therapy with trimethoprim/sulfamethoxazole (TMP/SMZ)[1][2][3]. Caspofungin is an echinocandin antifungal that inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, particularly effective against the cyst form of Pneumocystis jirovecii. Clindamycin is a lincosamide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit; its mechanism against P. jirovecii is not fully understood but may involve inhibition of protozoal and bacterial protein synthesis[5]. This combination has been reported to be beneficial in case reports and small series for moderate-to-severe PCP when first-line therapies are contraindicated or ineffective[1][2][3].